- Home
- Latest
- By speciality
- Biology
- Bone
- Brain and nervous system
- Breast
- Colorectal and gastrointestinal
- Community
- Diagnostics
- Drug development
- Epidemiology and prevention
- Haematology oncology
- Head and neck
- Hepatobiliary pancreatic
- Lung and pleura
- Melanoma and skin
- Ovary and gynaecology
- Paediatric
- Prostate and urology
- Psycho social
- Radiotherapy
- Sarcomas
- Surgery
- Other
- By congress
- By continent
- Latest technologies
- Most viewed
- Archive
- Contact us
- FAQ's
- Register
AACR 2009, Biology, Biomarkers, Cell therapy, Drugs in development, Europe, Targeted mo...
Flash player required
You do not have the correct version of the flash player required to view this content. Click here to install the free Adobe flash player.
Professor David Lane - Director of the Cancer Research UK Transformation Research Group, University of Dundee
AACR 2009: Tackling the p53 gene and side effects
Professor Sir David Lane is the Director of the Cancer Research UK Transformation Research Group at the University of Dundee, where he leads a research team studying human tumour suppressor gene function. Speaking at AACR 2009: Reactivating mutant p53 genes, tackling side effects of p53-specific molecules, while leaving the tumour susceptible to chemotherapy.
Specialities
- Biology (58)
- Bone (16)
- Brain and nervous system (14)
- Breast (143)
- Colorectal and gastrointestinal (32)
- Community (61)
- Diagnostics (27)
- Drug development (49)
- Epidemiology and prevention (42)
- Haematology oncology (39)
- Head and neck (17)
- Hepatobiliary pancreatic (15)
- Lung and pleura (30)
- Melanoma and skin (22)
- Ovary and gynaecology (29)
- Paediatric (17)
- Prostate and urology (32)
- Psycho social (19)
- Radiotherapy (18)
- Sarcomas (13)
- Surgery (24)
Content is the view and comment of the speakers or author and not of sponsoring companies or organisations. Organisation logo does not indicate endorsement.
Comments on this video Report unsuitable comment
No comments have been made on this video yet, be the first to voice your opinion, use the form on the right.
Add a comment